Shares of Capricor Therapeutics (CAPR) touched a 52-week high of $21.21 in early trading today, as anticipation builds for the upcoming release of long-term data from the company's ongoing HOPE-2 Open Label Extension Study.
The HOPE-2 open-label extension trial is a phase II study evaluating the company's lead drug candidate, Deramiocel (CAP-1002), for the treatment of Duchenne muscular dystrophy.
Subscribe to continue reading the article.
This article is part of our premium content offering.Subscribe with a RTTNews subscription.
Subscribe NowAlready subscribed? Sign in
For comments and feedback: editorial@rttnews.com